{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:37:30Z","timestamp":1787611050469,"version":"build-2736575974"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"DOI":"10.1007\/s10555-026-10342-1","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T03:01:19Z","timestamp":1779418879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Humoral immunity in pancreatic cancer: B-cell heterogeneity, regulatory networks, and therapeutic opportunities"],"prefix":"10.1007","volume":"45","author":[{"given":"Joshua","family":"Kalapala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Turunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle A.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Principe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"10342_CR1","volume":"76","author":"RL Siegel","year":"2026","unstructured":"Siegel, R. L., Kratzer, T. B., Wagle, N. S., Sung, H., & Jemal, A. (2026). Cancer statistics, 2026. CA: A Cancer Journal for Clinicians, 76, Article e70043.","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10342_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.688377","volume":"11","author":"DR Principe","year":"2021","unstructured":"Principe, D. R., Underwood, P. W., Korc, M., Trevino, J. G., Munshi, H. G., & Rana, A. (2021). The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy. Frontiers in Oncology, 11, Article 688377.","journal-title":"Frontiers in Oncology"},{"key":"10342_CR3","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024). Cancer statistics, 2024. CA: A Cancer Journal for Clinicians, 74, 12\u201349.","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10342_CR4","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley, R. K., Ueno, M., Yoo, C., Finn, R. S., Furuse, J., Ren, Z., et al. (2023). Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 401, 1853\u20131865.","journal-title":"Lancet"},{"key":"10342_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y., Shitara, K., Moehler, M., Garrido, M., Salman, P., Shen, L., et al. (2021). First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet, 398, 27\u201340.","journal-title":"Lancet"},{"key":"10342_CR6","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T. Y., et al. (2020). Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. New England Journal of Medicine, 382, 1894\u20131905.","journal-title":"New England Journal of Medicine"},{"key":"10342_CR7","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","volume":"23","author":"LA Diaz Jr","year":"2022","unstructured":"Diaz, L. A., Jr., Shiu, K. K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., et al. (2022). Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): Final analysis of a randomised, open-label, phase 3 study. The lancet Oncology, 23, 659\u2013670.","journal-title":"The lancet Oncology"},{"key":"10342_CR8","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng, A. L., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T. Y., et al. (2022). Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol, 76, 862\u201373.","journal-title":"J Hepatol"},{"key":"10342_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2021.01.031","volume":"504","author":"DR Principe","year":"2021","unstructured":"Principe, D. R., Korc, M., Kamath, S. D., Munshi, H. G., & Rana, A. (2021). Trials and tribulations of pancreatic cancer immunotherapy. Cancer Letters, 504, 1\u201314.","journal-title":"Cancer Letters"},{"key":"10342_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.seminoncol.2025.152411","volume":"52","author":"DA Guirguis","year":"2025","unstructured":"Guirguis, D. A., Hasan, F., Morris, N., Alabd, A., Tawfik, P. M. S., Pramanik, K., et al. (2025). Tumor tough, therapy smarter: Rethinking CAR-T for pancreatic cancer. Seminars in Oncology, 52, Article 152411.","journal-title":"Seminars in Oncology"},{"key":"10342_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2026.218417","volume":"646","author":"KA Burton","year":"2026","unstructured":"Burton, K. A., Metropulos, A. E., Kamath, S. D., Munshi, H. G., & Principe, D. R. (2026). Bispecific T-cell engager therapy for gastrointestinal cancers. Cancer Letters, 646, Article 218417.","journal-title":"Cancer Letters"},{"key":"10342_CR12","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/s41467-024-55424-2","volume":"16","author":"S Sivakumar","year":"2025","unstructured":"Sivakumar, S., Jainarayanan, A., Arbe-Barnes, E., Sharma, P. K., Leathlobhair, M. N., Amin, S., et al. (2025). Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms. Nature Communications, 16, 1397.","journal-title":"Nature Communications"},{"key":"10342_CR13","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1136\/gutjnl-2019-319912","volume":"70","author":"R Takahashi","year":"2021","unstructured":"Takahashi, R., Macchini, M., Sunagawa, M., Jiang, Z., Tanaka, T., Valenti, G., et al. (2021). Interleukin-1beta-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression. Gut, 70, 330\u2013341.","journal-title":"Gut"},{"key":"10342_CR14","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3389\/fimmu.2019.00542","volume":"10","author":"S Spear","year":"2019","unstructured":"Spear, S., Candido, J. B., McDermott, J. R., Ghirelli, C., Maniati, E., Beers, S. A., et al. (2019). Discrepancies in the tumor microenvironment of spontaneous and orthotopic murine models of pancreatic cancer uncover a new immunostimulatory phenotype for B cells. Frontiers in Immunology, 10, 542.","journal-title":"Frontiers in Immunology"},{"key":"10342_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1085147","volume":"5","author":"GF Castino","year":"2016","unstructured":"Castino, G. F., Cortese, N., Capretti, G., Serio, S., Di Caro, G., Mineri, R., et al. (2016). Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. Oncoimmunology, 5, Article e1085147.","journal-title":"Oncoimmunology"},{"key":"10342_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1158\/2159-8290.CD-15-0827","volume":"6","author":"AJ Gunderson","year":"2016","unstructured":"Gunderson, A. J., Kaneda, M. M., Tsujikawa, T., Nguyen, A. V., Affara, N. I., Ruffell, B., et al. (2016). Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. Cancer Discovery, 6, 270\u2013285.","journal-title":"Cancer Discovery"},{"key":"10342_CR17","doi-asserted-by":"publisher","first-page":"1794359","DOI":"10.1080\/2162402X.2020.1794359","volume":"9","author":"C Minici","year":"2020","unstructured":"Minici, C., Rigamonti, E., Lanzillotta, M., Monno, A., Rovati, L., Maehara, T., et al. (2020). B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma. Oncoimmunology, 9, 1794359.","journal-title":"Oncoimmunology"},{"key":"10342_CR18","doi-asserted-by":"crossref","unstructured":"Diskin, B., Adam, S., Soto, GS., Liria, M., Aykut, B., Sundberg, B., et al. (2022). BTLA(+)CD200(+) B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer. Oncogene, 41, 4349\u201360.","DOI":"10.1038\/s41388-022-02425-4"},{"key":"10342_CR19","doi-asserted-by":"crossref","unstructured":"Greene, E., Horvat, NK., Doxie, DB., Parihar, VC., Kim, J., Herting, CJ., et al. (2025). High-dimensional protein analysis uncovers distinct immunological and stromal features in primary and metastatic pancreatic ductal adenocarcinoma. Cancer Res,\u00a086(7):1753\u20131768.","DOI":"10.1158\/0008-5472.CAN-25-1697"},{"key":"10342_CR20","doi-asserted-by":"crossref","unstructured":"Gaspar, CF., Marret, G., Wu, BZ., Bruce, J., Stone, SC., Wang, BX., et al.\u00a0(2025). Integrative analysis of tumor microenvironment in advanced pancreatic cancer: Unraveling genomic and immune landscape for targeted therapies. Journal of Clinical Oncology, 43, 4182-.","DOI":"10.1200\/JCO.2025.43.16_suppl.4182"},{"key":"10342_CR21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","volume":"42","author":"EC Rosser","year":"2015","unstructured":"Rosser, E. C., & Mauri, C. (2015). Regulatory B cells: Origin, phenotype, and function. Immunity, 42, 607\u2013612.","journal-title":"Immunity"},{"key":"10342_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105098","volume":"103","author":"H Zhu","year":"2024","unstructured":"Zhu, H., Xu, J., Wang, W., Zhang, B., Liu, J., Liang, C., et al. (2024). Intratumoral CD38(+)CD19(+)B cells associate with poor clinical outcomes and immunosuppression in patients with pancreatic ductal adenocarcinoma. eBioMedicine, 103, Article 105098.","journal-title":"eBioMedicine"},{"key":"10342_CR23","doi-asserted-by":"crossref","unstructured":"Zhong, Q., Hao, H., Li, S., Ning, Y., Li, H., Hu, X., et al. (2024). B cell c-Maf signaling promotes tumor progression in animal models of pancreatic cancer and melanoma. J Immunother Cancer, 12(11):e009861.","DOI":"10.1136\/jitc-2024-009861"},{"key":"10342_CR24","doi-asserted-by":"publisher","first-page":"14803","DOI":"10.18632\/oncotarget.22976","volume":"9","author":"Y Zhao","year":"2018","unstructured":"Zhao, Y., Shen, M., Feng, Y., He, R., Xu, X., Xie, Y., et al. (2018). Regulatory B cells induced by pancreatic cancer cell-derived Interleukin-18 promote immune tolerance via the PD-1\/PD-L1 pathway. Oncotarget, 9, 14803\u201314814.","journal-title":"Oncotarget"},{"key":"10342_CR25","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nm.3554","volume":"20","author":"RX Wang","year":"2014","unstructured":"Wang, R. X., Yu, C. R., Dambuza, I. M., Mahdi, R. M., Dolinska, M. B., Sergeev, Y. V., et al. (2014). Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nature Medicine, 20, 633\u2013641.","journal-title":"Nature Medicine"},{"key":"10342_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2019.154817","volume":"125","author":"D Michaud","year":"2020","unstructured":"Michaud, D., Mirlekar, B., Bischoff, S., Cowley, D. O., Vignali, D. A. A., & Pylayeva-Gupta, Y. (2020). Pancreatic cancer-associated inflammation drives dynamic regulation of p35 and Ebi3. Cytokine, 125, Article 154817.","journal-title":"Cytokine"},{"key":"10342_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.745873","volume":"12","author":"D Michaud","year":"2021","unstructured":"Michaud, D., Mirlekar, B., Steward, C., Bishop, G., & Pylayeva-Gupta, Y. (2021). B cell receptor signaling and protein kinase D2 support regulatory B cell function in pancreatic cancer. Frontiers in Immunology, 12, Article 745873.","journal-title":"Frontiers in Immunology"},{"key":"10342_CR28","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1158\/2326-6066.CIR-17-0710","volume":"6","author":"B Mirlekar","year":"2018","unstructured":"Mirlekar, B., Michaud, D., Searcy, R., Greene, K., & Pylayeva-Gupta, Y. (2018). IL35 hinders endogenous antitumor T-cell immunity and responsiveness to immunotherapy in pancreatic cancer. Cancer Immunology Research, 6, 1014\u20131024.","journal-title":"Cancer Immunology Research"},{"key":"10342_CR29","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1158\/2326-6066.CIR-19-0349","volume":"8","author":"B Mirlekar","year":"2020","unstructured":"Mirlekar, B., Michaud, D., Lee, S. J., Kren, N. P., Harris, C., Greene, K., et al. (2020). B cell-derived IL35 drives STAT3-dependent CD8(+) T-cell exclusion in pancreatic cancer. Cancer Immunology Research, 8, 292\u2013308.","journal-title":"Cancer Immunology Research"},{"key":"10342_CR30","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1038\/s41388-018-0668-3","volume":"38","author":"S Das","year":"2019","unstructured":"Das, S., & Bar-Sagi, D. (2019). BTK signaling drives CD1d(hi)CD5(+) regulatory B-cell differentiation to promote pancreatic carcinogenesis. Oncogene, 38, 3316\u20133324.","journal-title":"Oncogene"},{"key":"10342_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.immuni.2020.05.013","volume":"53","author":"X Zhang","year":"2020","unstructured":"Zhang, X., Bai, X. C., & Chen, Z. J. (2020). Structures and mechanisms in the cGAS-STING innate immunity pathway. Immunity, 53, 43\u201353.","journal-title":"Immunity"},{"key":"10342_CR32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s40425-019-0573-5","volume":"7","author":"W Jing","year":"2019","unstructured":"Jing, W., McAllister, D., Vonderhaar, E. P., Palen, K., Riese, M. J., Gershan, J., et al. (2019). STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models. Journal for Immunotherapy of Cancer, 7, 115.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10342_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adj9366","volume":"16","author":"L Chibaya","year":"2024","unstructured":"Chibaya, L., DeMarco, K. D., Lusi, C. F., Kane, G. I., Brassil, M. L., Parikh, C. N., et al. (2024). Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. Science Translational Medicine, 16, Article eadj9366.","journal-title":"Science Translational Medicine"},{"key":"10342_CR34","doi-asserted-by":"crossref","unstructured":"Ager, CR., Boda, A., Rajapakshe, K., Lea, ST., Di Francesco, ME., Jayaprakash, P., et al. (2021). High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. J Immunother Cancer, 9(8):e003246.","DOI":"10.1136\/jitc-2021-003246"},{"key":"10342_CR35","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1158\/1078-0432.CCR-22-3322","volume":"29","author":"R Ghukasyan","year":"2023","unstructured":"Ghukasyan, R., Liang, K., Chau, K., Li, L., Chan, C., Abt, E. R., et al. (2023). MEK inhibition sensitizes pancreatic cancer to STING agonism by tumor cell-intrinsic amplification of type I IFN signaling. Clinical Cancer Research, 29, 3130\u20133141.","journal-title":"Clinical Cancer Research"},{"key":"10342_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41586-022-05254-3","volume":"610","author":"S Li","year":"2022","unstructured":"Li, S., Mirlekar, B., Johnson, B. M., Brickey, W. J., Wrobel, J. A., Yang, N., et al. (2022). STING-induced regulatory B cells compromise NK function in cancer immunity. Nature, 610, 373\u2013380.","journal-title":"Nature"},{"key":"10342_CR37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1158\/2159-8290.CD-15-0843","volume":"6","author":"Y Pylayeva-Gupta","year":"2016","unstructured":"Pylayeva-Gupta, Y., Das, S., Handler, J. S., Hajdu, C. H., Coffre, M., Koralov, S. B., et al. (2016). IL35-producing B cells promote the development of pancreatic neoplasia. Cancer Discovery, 6, 247\u2013255.","journal-title":"Cancer Discovery"},{"key":"10342_CR38","volume":"13","author":"H Li","year":"2026","unstructured":"Li, H., Sun, H., Liu, J., Wu, Y., Wei, L., Li, J., et al. (2026). Tumor-derived interleukin 35 promotes fibrosis in the tumor microenvironment of pancreatic cancer by activating pancreatic stellate cells. Advanced Science (Weinheim, Germany), 13, Article e09074.","journal-title":"Advanced Science (Weinheim, Germany)"},{"key":"10342_CR39","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1053\/j.gastro.2017.09.039","volume":"154","author":"C Huang","year":"2018","unstructured":"Huang, C., Li, Z., Li, N., Li, Y., Chang, A., Zhao, T., et al. (2018). Interleukin 35 expression correlates with microvessel density in pancreatic ductal adenocarcinoma, recruits monocytes, and promotes growth and angiogenesis of xenograft tumors in mice. Gastroenterology, 154, 675\u2013688.","journal-title":"Gastroenterology"},{"key":"10342_CR40","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41388-024-02938-0","volume":"43","author":"H Sun","year":"2024","unstructured":"Sun, H., Ge, Y., Liu, J., Li, Z., Li, H., Zhao, T., et al. (2024). Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma. Oncogene, 43, 776\u2013788.","journal-title":"Oncogene"},{"key":"10342_CR41","doi-asserted-by":"publisher","first-page":"14035","DOI":"10.1038\/ncomms14035","volume":"8","author":"C Huang","year":"2017","unstructured":"Huang, C., Li, N., Li, Z., Chang, A., Chen, Y., Zhao, T., et al. (2017). Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression. Nature Communications, 8, 14035.","journal-title":"Nature Communications"},{"key":"10342_CR42","doi-asserted-by":"crossref","unstructured":"Yao, M., Preall, J., Yeh, JT., Pappin, D., Cifani, P., Zhao, Y., et al. (2023). Plasma cells in human pancreatic ductal adenocarcinoma secrete antibodies against self-antigens. JCI Insight, 8(21):e172449.","DOI":"10.1172\/jci.insight.172449"},{"key":"10342_CR43","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/cmi.2010.13","volume":"7","author":"X Zhu","year":"2010","unstructured":"Zhu, X., Wu, L., Zhang, L., Hao, P., Zhang, S., Huang, J., et al. (2010). Distinct regulatory mechanism of immunoglobulin gene transcription in epithelial cancer cells. Cellular & Molecular Immunology, 7, 279\u2013286.","journal-title":"Cellular & Molecular Immunology"},{"key":"10342_CR44","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-981-97-0511-5_3","volume":"1445","author":"M Xia","year":"2024","unstructured":"Xia, M., Zhang, C., Xiao, L., & Qiu, X. (2024). Genetic characteristics of non B cell-derived immunoglobulin genes. Advances in Experimental Medicine and Biology, 1445, 37\u201346.","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10342_CR45","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1097\/MPA.0000000000000544","volume":"44","author":"X Wan","year":"2015","unstructured":"Wan, X., Lei, Y., Li, Z., Wang, J., Chen, Z., McNutt, M., et al. (2015). Pancreatic expression of immunoglobulin G in human pancreatic cancer and associated diabetes. Pancreas, 44, 1304\u20131313.","journal-title":"Pancreas"},{"key":"10342_CR46","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.7150\/jca.39800","volume":"11","author":"M Cui","year":"2020","unstructured":"Cui, M., You, L., Zheng, B., Huang, X., Liu, Q., Huang, J., et al. (2020). High expression of cancer-derived glycosylated immunoglobulin G predicts poor prognosis in pancreatic ductal adenocarcinoma. Journal of Cancer, 11, 2213\u20132221.","journal-title":"Journal of Cancer"},{"key":"10342_CR47","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/978-981-97-0511-5_10","volume":"1445","author":"M Cui","year":"2024","unstructured":"Cui, M., & Qiu, X. (2024). Cancer-derived immunoglobulin G and pancreatic cancer. Advances in Experimental Medicine and Biology, 1445, 129\u2013135.","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10342_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1330419","volume":"14","author":"PWM Maimela","year":"2024","unstructured":"Maimela, P. W. M., Smith, M., Nel, A. J. M., Bernam, S. D. P., Jonas, E. G., & Blackburn, J. M. (2024). Humoral immunoprofiling identifies novel biomarkers and an immune suppressive autoantibody phenotype at the site of disease in pancreatic ductal adenocarcinoma. Frontiers in Oncology, 14, Article 1330419.","journal-title":"Frontiers in Oncology"},{"key":"10342_CR49","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41577-023-00871-z","volume":"23","author":"T Rispens","year":"2023","unstructured":"Rispens, T., & Huijbers, M. G. (2023). The unique properties of IgG4 and its roles in health and disease. Nature Reviews. Immunology, 23, 763\u2013778.","journal-title":"Nature Reviews. Immunology"},{"key":"10342_CR50","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jmb.2013.10.039","volume":"426","author":"AM Davies","year":"2014","unstructured":"Davies, A. M., Rispens, T., Ooijevaar-de Heer, P., Gould, H. J., Jefferis, R., Aalberse, R. C., et al. (2014). Structural determinants of unique properties of human IgG4-Fc. Journal of Molecular Biology, 426, 630\u2013644.","journal-title":"Journal of Molecular Biology"},{"key":"10342_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104819","volume":"97","author":"L De Monte","year":"2023","unstructured":"De Monte, L., Clemente, F., Ruggiero, E., Pini, R., Ceraolo, M. G., Schiavo Lena, M., et al. (2023). Pro-tumor Tfh2 cells induce detrimental IgG4 production and PGE(2)-dependent IgE inhibition in pancreatic cancer. eBioMedicine, 97, Article 104819.","journal-title":"eBioMedicine"},{"key":"10342_CR52","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00262-016-1853-2","volume":"65","author":"Q Liu","year":"2016","unstructured":"Liu, Q., Niu, Z., Li, Y., Wang, M., Pan, B., Lu, Z., et al. (2016). Immunoglobulin G4 (IgG4)-positive plasma cell infiltration is associated with the clinicopathologic traits and prognosis of pancreatic cancer after curative resection. Cancer Immunology, Immunotherapy, 65, 931\u2013940.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10342_CR53","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/MPA.0000000000000297","volume":"44","author":"T Ngwa","year":"2015","unstructured":"Ngwa, T., Law, R., Hart, P., Smyrk, T. C., & Chari, S. T. (2015). Serum IgG4 elevation in pancreatic cancer: Diagnostic and prognostic significance and association with autoimmune pancreatitis. Pancreas, 44, 557\u2013560.","journal-title":"Pancreas"},{"key":"10342_CR54","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/j.1572-0241.2007.01264.x","volume":"102","author":"A Ghazale","year":"2007","unstructured":"Ghazale, A., Chari, S. T., Smyrk, T. C., Levy, M. J., Topazian, M. D., Takahashi, N., et al. (2007). Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. American Journal of Gastroenterology, 102, 1646\u20131653.","journal-title":"American Journal of Gastroenterology"},{"key":"10342_CR55","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/modpathol.3800689","volume":"20","author":"L Zhang","year":"2007","unstructured":"Zhang, L., Notohara, K., Levy, M. J., Chari, S. T., & Smyrk, T. C. (2007). IgG4-positive plasma cell infiltration in the diagnosis of autoimmune pancreatitis. Modern Pathology, 20, 23\u201328.","journal-title":"Modern Pathology"},{"key":"10342_CR56","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/pin.12136","volume":"64","author":"T Uehara","year":"2014","unstructured":"Uehara, T., Hamano, H., Kawa, S., Kobayashi, Y., Yoshizawa, A., Oki, K., et al. (2014). Comparison of histopathological features of pancreatic carcinoma and type 1 autoimmune pancreatitis. Pathology International, 64, 51\u201357.","journal-title":"Pathology International"},{"key":"10342_CR57","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.bbrc.2005.02.181","volume":"330","author":"Q Xia","year":"2005","unstructured":"Xia, Q., Kong, X. T., Zhang, G. A., Hou, X. J., Qiang, H., & Zhong, R. Q. (2005). Proteomics-based identification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer. Biochemical and Biophysical Research Communications, 330, 526\u2013532.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10342_CR58","doi-asserted-by":"publisher","first-page":"5504","DOI":"10.1158\/0008-5472.CAN-04-0077","volume":"64","author":"SH Hong","year":"2004","unstructured":"Hong, S. H., Misek, D. E., Wang, H., Puravs, E., Giordano, T. J., Greenson, J. K., et al. (2004). An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Research, 64, 5504\u20135510.","journal-title":"Cancer Research"},{"key":"10342_CR59","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/ijc.34334","volume":"152","author":"L Zhuang","year":"2023","unstructured":"Zhuang, L., Huang, C., Ning, Z., Yang, L., Zou, W., Wang, P., et al. (2023). Circulating tumor-associated autoantibodies as novel diagnostic biomarkers in pancreatic adenocarcinoma. International Journal of Cancer, 152, 1013\u20131024.","journal-title":"International Journal of Cancer"},{"key":"10342_CR60","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.pan.2019.06.009","volume":"19","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y., Cui, J., & Du, H. (2019). Autoantibody-targeted TAAs in pancreatic cancer: A comprehensive analysis. Pancreatology\u202f: official journal of the International Association of Pancreatology, 19, 760\u2013768.","journal-title":"Pancreatology : official journal of the International Association of Pancreatology"},{"key":"10342_CR61","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1021\/pr100213b","volume":"10","author":"B Tomaino","year":"2011","unstructured":"Tomaino, B., Cappello, P., Capello, M., Fredolini, C., Sperduti, I., Migliorini, P., et al. (2011). Circulating autoantibodies to phosphorylated alpha-enolase are a hallmark of pancreatic cancer. Journal of Proteome Research, 10, 105\u2013112.","journal-title":"Journal of Proteome Research"},{"key":"10342_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1494446","volume":"16","author":"MO Mowoe","year":"2025","unstructured":"Mowoe, M. O., Allam, H., Nqada, J., Bernon, M., Gandhi, K., Burmeister, S., et al. (2025). Identification and validation of a novel autoantibody biomarker panel for differential diagnosis of pancreatic ductal adenocarcinoma. Frontiers in Immunology, 16, Article 1494446.","journal-title":"Frontiers in Immunology"},{"key":"10342_CR63","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12935-023-03107-1","volume":"23","author":"T Li","year":"2023","unstructured":"Li, T., Xia, J., Yun, H., Sun, G., Shen, Y., Wang, P., et al. (2023). A novel autoantibody signatures for enhanced clinical diagnosis of pancreatic ductal adenocarcinoma. Cancer Cell International, 23, 273.","journal-title":"Cancer Cell International"},{"key":"10342_CR64","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1365-3083.2011.02657.x","volume":"75","author":"J Li","year":"2012","unstructured":"Li, J., Wang, L. J., Ying, X., Han, S. X., Bai, E., Zhang, Y., et al. (2012). Immunodiagnostic value of combined detection of autoantibodies to tumor-associated antigens as biomarkers in pancreatic cancer. Scandinavian Journal of Immunology, 75, 342\u2013349.","journal-title":"Scandinavian Journal of Immunology"},{"key":"10342_CR65","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.imlet.2015.06.008","volume":"167","author":"M Capello","year":"2015","unstructured":"Capello, M., Caorsi, C., Bogantes Hernandez, P. J., Dametto, E., Bertinetto, F. E., Magistroni, P., et al. (2015). Phosphorylated alpha-enolase induces autoantibodies in HLA-DR8 pancreatic cancer patients and triggers HLA-DR8 restricted T-cell activation. Immunology Letters, 167, 11\u201316.","journal-title":"Immunology Letters"},{"key":"10342_CR66","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1002\/cncr.27538","volume":"118","author":"PM Bracci","year":"2012","unstructured":"Bracci, P. M., Zhou, M., Young, S., & Wiemels, J. (2012). Serum autoantibodies to pancreatic cancer antigens as biomarkers of pancreatic cancer in a San Francisco Bay Area case-control study. Cancer, 118, 5384\u20135394.","journal-title":"Cancer"},{"key":"10342_CR67","doi-asserted-by":"publisher","first-page":"11151","DOI":"10.18632\/oncotarget.7098","volume":"7","author":"K Dumstrei","year":"2016","unstructured":"Dumstrei, K., Chen, H., & Brenner, H. (2016). A systematic review of serum autoantibodies as biomarkers for pancreatic cancer detection. Oncotarget, 7, 11151\u201311164.","journal-title":"Oncotarget"},{"key":"10342_CR68","doi-asserted-by":"publisher","DOI":"10.1111\/sji.70012","volume":"101","author":"Y Liu","year":"2025","unstructured":"Liu, Y., Gao, Y., Wu, Y., Wu, W., Yu, J., Ma, S., et al. (2025). Autoantibodies as potential liquid biopsy biomarker in detection of pancreatic cancer: A diagnostic test accuracy review and meta-analysis. Scandinavian Journal of Immunology, 101, Article e70012.","journal-title":"Scandinavian Journal of Immunology"},{"key":"10342_CR69","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1053\/j.gastro.2025.08.034","volume":"170","author":"AL Lucas","year":"2026","unstructured":"Lucas, A. L., Simeone, D. M., Katona, B. W., Paiella, S., Zogopoulos, G., Sears, R. C., et al. (2026). Validation of a serum-based biomarker signature for detection of early-stage pancreatic ductal adenocarcinoma. Gastroenterology, 170, 375\u2013384.","journal-title":"Gastroenterology"},{"key":"10342_CR70","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000468","volume":"13","author":"RE Brand","year":"2022","unstructured":"Brand, R. E., Persson, J., Bratlie, S. O., Chung, D. C., Katona, B. W., Carrato, A., et al. (2022). Detection of early-stage pancreatic ductal adenocarcinoma from blood samples: Results of a multiplex biomarker signature validation study. Clinical and Translational Gastroenterology, 13, Article e00468.","journal-title":"Clinical and Translational Gastroenterology"},{"key":"10342_CR71","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pan.2025.11.017","volume":"26","author":"L Sun","year":"2026","unstructured":"Sun, L., Liu, Y., Yang, Q., Zhu, J., Li, T., Jiang, D., et al. (2026). Serum autoantibody signatures enable non-invasive early detection of pancreatic cancer. Pancreatology, 26, 114\u2013122.","journal-title":"Pancreatology"},{"key":"10342_CR72","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/j.1365-2249.2008.03726.x","volume":"153","author":"SL Fu","year":"2008","unstructured":"Fu, S. L., Pierre, J., Smith-Norowitz, T. A., Hagler, M., Bowne, W., Pincus, M. R., et al. (2008). Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells. Clinical and Experimental Immunology, 153, 401\u2013409.","journal-title":"Clinical and Experimental Immunology"},{"key":"10342_CR73","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s00262-019-02413-w","volume":"68","author":"Y Kasahara","year":"2019","unstructured":"Kasahara, Y., Shirota, H., Umegaki, S., & Ishioka, C. (2019). Contribution of Fcgamma receptor IIB to creating a suppressive tumor microenvironment in a mouse model. Cancer Immunology, Immunotherapy, 68, 1769\u20131778.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10342_CR74","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s41419-019-2065-4","volume":"10","author":"R Zhang","year":"2019","unstructured":"Zhang, R., Liu, Q., Peng, J., Wang, M., Gao, X., Liao, Q., et al. (2019). Pancreatic cancer-educated macrophages protect cancer cells from complement-dependent cytotoxicity by up-regulation of CD59. Cell Death & Disease, 10, 836.","journal-title":"Cell Death & Disease"},{"key":"10342_CR75","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41467-018-08109-6","volume":"10","author":"M Capello","year":"2019","unstructured":"Capello, M., Vykoukal, J. V., Katayama, H., Bantis, L. E., Wang, H., Kundnani, D. L., et al. (2019). Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Nature Communications, 10, 254.","journal-title":"Nature Communications"},{"key":"10342_CR76","doi-asserted-by":"crossref","unstructured":"Mandili, G., Curcio, C., Bulfamante, S., Follia, L., Ferrero, G., Mazza, E., et al. (2020). In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination. J Immunother Cancer, 8(2), e001071.","DOI":"10.1136\/jitc-2020-001071"},{"key":"10342_CR77","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41698-025-00848-2","volume":"9","author":"X Zhang","year":"2025","unstructured":"Zhang, X., Lan, R., Liu, Y., Pillarisetty, V. G., Li, D., Zhao, C. L., et al. (2025). Complement activation in tumor microenvironment after neoadjuvant therapy and its impact on pancreatic cancer outcomes. npj Precision Oncology, 9, 58.","journal-title":"npj Precision Oncology"},{"key":"10342_CR78","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3389\/fimmu.2015.00257","volume":"6","author":"NS Merle","year":"2015","unstructured":"Merle, N. S., Noe, R., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V., & Roumenina, L. T. (2015). Complement system Part II: Role in immunity. Frontiers in Immunology, 6, 257.","journal-title":"Frontiers in Immunology"},{"key":"10342_CR79","doi-asserted-by":"crossref","unstructured":"Merle, N. S., Church, S. E., Fremeaux-Bacchi, V., & Roumenina, L. T. (2015). Complement system part I - Molecular mechanisms of activation and regulation. Frontiers in Immunology, 6, 262.","DOI":"10.3389\/fimmu.2015.00262"},{"key":"10342_CR80","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/cr.2009.139","volume":"20","author":"JR Dunkelberger","year":"2010","unstructured":"Dunkelberger, J. R., & Song, W. C. (2010). Complement and its role in innate and adaptive immune responses. Cell Research, 20, 34\u201350.","journal-title":"Cell Research"},{"key":"10342_CR81","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1158\/1535-7163.MCT-24-0898","volume":"25","author":"M Gao","year":"2026","unstructured":"Gao, M., Kechagia, S., Ramachandran, M., Manivel, V. A., Kadri, N., Cicortas, B. A., et al. (2026). Shaping tumor microenvironment by amplifying the complement cascade for improved immune response in pancreatic cancer model. Molecular Cancer Therapeutics, 25, 469\u2013479.","journal-title":"Molecular Cancer Therapeutics"},{"key":"10342_CR82","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.21873\/anticanres.15587","volume":"42","author":"R Suzuki","year":"2022","unstructured":"Suzuki, R., Okubo, Y., Takagi, T., Sugimoto, M., Sato, Y., Irie, H., et al. (2022). The complement C3a\u2013C3a receptor axis regulates epithelial-to-mesenchymal transition by activating the ERK pathway in pancreatic ductal adenocarcinoma. Anticancer Research, 42, 1207\u20131215.","journal-title":"Anticancer Research"},{"key":"10342_CR83","doi-asserted-by":"publisher","first-page":"5743","DOI":"10.21873\/anticanres.16081","volume":"42","author":"R Suzuki","year":"2022","unstructured":"Suzuki, R., Takagi, T., Sugimoto, M., Sato, Y., Irie, H., Yomogida, Y., et al. (2022). Intracellular C3 modulates EMT via the Akt\/Smad pathway in pancreatic cancer cells. Anticancer Research, 42, 5743\u201350.","journal-title":"Anticancer Research"},{"key":"10342_CR84","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1038\/s41416-025-03185-0","volume":"133","author":"R Eto","year":"2025","unstructured":"Eto, R., Takano, S., Zhou, D., Suzuki, K., Takayashiki, T., Suzuki, D., et al. (2025). Inhibition of C5a\u2013C5aR1 axis suppresses tumour progression by enhancing antitumour immunity and chemotherapeutic effect in pancreatic ductal adenocarcinoma. British Journal of Cancer, 133, 1791\u20131801.","journal-title":"British Journal of Cancer"},{"key":"10342_CR85","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00262-025-04249-z","volume":"75","author":"S Yang","year":"2025","unstructured":"Yang, S., Xiao, L., Qi, P., Liu, Z., Chen, Z., Wei, R., et al. (2025). Chronic stress promotes pancreatic ductal adenocarcinoma progression via complement C5a-recruited myeloid-derived suppressor cells. Cancer Immunology, Immunotherapy, 75, 11.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10342_CR86","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.neo.2019.09.003","volume":"21","author":"K Saito","year":"2019","unstructured":"Saito, K., Iioka, H., Maruyama, S., Sumardika, I. W., Sakaguchi, M., & Kondo, E. (2019). PODXL1 promotes metastasis of the pancreatic ductal adenocarcinoma by activating the C5aR\/C5a axis from the tumor microenvironment. Neoplasia (New York, N.Y.), 21, 1121\u20131132.","journal-title":"Neoplasia (New York, N.Y.)"},{"key":"10342_CR87","doi-asserted-by":"publisher","first-page":"10769","DOI":"10.1038\/s41467-025-65811-y","volume":"16","author":"A Langtry","year":"2025","unstructured":"Langtry, A., Rabadan, R., Alonso, L., Filip, I., Sabroso-Lasa, S., Moreno-Oya, A., et al. (2025). Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Nature Communications, 16, 10769.","journal-title":"Nature Communications"},{"key":"10342_CR88","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/CJI.0b013e3181bed29f","volume":"33","author":"A Marten","year":"2010","unstructured":"Marten, A., Buchler, M. W., Werft, W., Wente, M. N., Kirschfink, M., & Schmidt, J. (2010). Soluble iC3b as an early marker for pancreatic adenocarcinoma is superior to CA19.9 and radiology. Journal of Immunotherapy, 33, 219\u2013224.","journal-title":"Journal of Immunotherapy"},{"key":"10342_CR89","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1021\/acs.jproteome.1c00805","volume":"20","author":"MJ Lee","year":"2021","unstructured":"Lee, M. J., Na, K., Shin, H., Kim, C. Y., Cho, J. Y., Kang, C. M., et al. (2021). Early diagnostic ability of human complement factor B in pancreatic cancer is partly linked to its potential tumor-promoting role. Journal of Proteome Research, 20, 5315\u20135328.","journal-title":"Journal of Proteome Research"},{"key":"10342_CR90","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1021\/pr5002719","volume":"13","author":"MJ Lee","year":"2014","unstructured":"Lee, M. J., Na, K., Jeong, S. K., Lim, J. S., Kim, S. A., Lee, M. J., et al. (2014). Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma. Journal of Proteome Research, 13, 4878\u20134888.","journal-title":"Journal of Proteome Research"},{"key":"10342_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061791","author":"MA Ullah","year":"2023","unstructured":"Ullah, M. A., & Mackay, F. (2023). The BAFF-APRIL system in cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15061791","journal-title":"Cancers (Basel)"},{"key":"10342_CR92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071367","volume":"8","author":"M Koizumi","year":"2013","unstructured":"Koizumi, M., Hiasa, Y., Kumagi, T., Yamanishi, H., Azemoto, N., Kobata, T., et al. (2013). Increased B cell-activating factor promotes tumor invasion and metastasis in human pancreatic cancer. PLoS ONE, 8, Article e71367.","journal-title":"PLoS ONE"},{"key":"10342_CR93","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1515\/CCLM.2011.608","volume":"49","author":"F Wang","year":"2011","unstructured":"Wang, F., Chen, L., Ding, W., Wang, G., Wu, Y., Wang, J., et al. (2011). Serum APRIL, a potential tumor marker in pancreatic cancer. Clinical Chemistry and Laboratory Medicine, 49, 1715\u20131719.","journal-title":"Clinical Chemistry and Laboratory Medicine"},{"key":"10342_CR94","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.3892\/mmr.2014.2443","volume":"10","author":"L Han","year":"2014","unstructured":"Han, L., Zhang, W., Song, F., Guo, Y., Guo, K., & Zhou, W. (2014). Soluble a-proliferation-inducing ligand (sAPRIL), a novel serum biomarker predicting the recurrence and metastasis of pancreatic adenocarcinoma after surgery. Molecular Medicine Reports, 10, 1978\u20131984.","journal-title":"Molecular Medicine Reports"},{"key":"10342_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7070175","author":"I Pombeiro","year":"2018","unstructured":"Pombeiro, I., Loosen, S. H., Roy, S., Schueller, F., Niewenhuisen, L., Luedde, M., et al. (2018). Differential roles of tumor necrosis factor ligand superfamily members as biomarkers in pancreatic cancer. Journal of Clinical Medicine. https:\/\/doi.org\/10.3390\/jcm7070175","journal-title":"Journal of Clinical Medicine"},{"key":"10342_CR96","first-page":"155","volume":"1","author":"AA Mihas","year":"1981","unstructured":"Mihas, A. A., Volanakis, J. E., Schrohenloher, R. E., & Mihas, T. A. (1981). Circulating immune complexes in carcinoma of the pancreas. Anticancer Research, 1, 155\u2013158.","journal-title":"Anticancer Research"},{"key":"10342_CR97","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/cas.13181","volume":"108","author":"M Satoh","year":"2017","unstructured":"Satoh, M., Takano, S., Sogawa, K., Noda, K., Yoshitomi, H., Ishibashi, M., et al. (2017). Immune-complex level of cofilin-1 in sera is associated with cancer progression and poor prognosis in pancreatic cancer. Cancer Science, 108, 795\u2013803.","journal-title":"Cancer Science"},{"key":"10342_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030746","author":"G Mandili","year":"2020","unstructured":"Mandili, G., Follia, L., Ferrero, G., Katayama, H., Hong, W., Momin, A. A., et al. (2020). Immune-complexome analysis identifies immunoglobulin-bound biomarkers that predict the response to chemotherapy of pancreatic cancer patients. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12030746","journal-title":"Cancers (Basel)"},{"key":"10342_CR99","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/00005792-199611000-00001","volume":"75","author":"HD Ochs","year":"1996","unstructured":"Ochs, H. D., & Smith, C. I. (1996). X-linked agammaglobulinemia. A clinical and molecular analysis. Medicine, 75, 287\u2013299.","journal-title":"Medicine"},{"key":"10342_CR100","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1016\/S1470-2045(19)30795-8","volume":"21","author":"ES Christenson","year":"2020","unstructured":"Christenson, E. S., Jaffee, E., & Azad, N. S. (2020). Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: A bright future. The Lancet Oncology, 21, e135\u2013e145.","journal-title":"The Lancet Oncology"},{"issue":"1","key":"10342_CR101","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4049\/jimmunol.1302570","volume":"193","author":"MJ Benson","year":"2014","unstructured":"Benson, M. J., Rodriguez, V., von Schack, D., Keegan, S., Cook, T. A., Edmonds, J., et al. (2014). Modeling the clinical phenotype of BTK inhibition in the mature murine immune system. The Journal of Immunology, 193(1), 185\u2013197.","journal-title":"The Journal of Immunology"},{"key":"10342_CR102","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005425","author":"M Sinha","year":"2023","unstructured":"Sinha, M., Betts, C., Zhang, L., Griffith, M. J., Solman, I., Chen, B., et al. (2023). Modulation of myeloid and T cells in vivo by Bruton\u2019s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma. Journal for ImmunoTherapy of Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-005425","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10342_CR103","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.annonc.2021.01.070","volume":"32","author":"M Tempero","year":"2021","unstructured":"Tempero, M., Oh, D. Y., Tabernero, J., Reni, M., Van Cutsem, E., Hendifar, A., et al. (2021). Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: Phase III RESOLVE study. Annals of Oncology, 32, 600\u2013608.","journal-title":"Annals of Oncology"},{"key":"10342_CR104","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000500571","volume":"97","author":"D Hong","year":"2019","unstructured":"Hong, D., Rasco, D., Veeder, M., Luke, J. J., Chandler, J., Balmanoukian, A., et al. (2019). A phase 1b\/2 study of the bruton tyrosine kinase inhibitor ibrutinib and the PD-L1 inhibitor durvalumab in patients with pretreated solid tumors. Oncology, 97, 102\u2013111.","journal-title":"Oncology"},{"key":"10342_CR105","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000587","author":"M Overman","year":"2020","unstructured":"Overman, M., Javle, M., Davis, R. E., Vats, P., Kumar-Sinha, C., Xiao, L., et al. (2020). Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. Journal for ImmunoTherapy of Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-000587","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10342_CR106","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.ymthe.2020.07.017","volume":"28","author":"AH Ko","year":"2020","unstructured":"Ko, A. H., Jordan, A. C., Tooker, E., Lacey, S. F., Chang, R. B., Li, Y., et al. (2020). Dual targeting of mesothelin and CD19 with chimeric antigen receptor-modified T cells in patients with metastatic pancreatic cancer. Molecular Therapy, 28, 2367\u20132378.","journal-title":"Molecular Therapy"},{"key":"10342_CR107","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00262-018-2145-9","volume":"67","author":"JK Winkler","year":"2018","unstructured":"Winkler, J. K., Schiller, M., Bender, C., Enk, A. H., & Hassel, J. C. (2018). Rituximab as a therapeutic option for patients with advanced melanoma. Cancer Immunology, Immunotherapy, 67, 917\u2013924.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10342_CR108","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12967-020-02370-4","volume":"18","author":"ST Ryan","year":"2020","unstructured":"Ryan, S. T., Zhang, J., Burner, D. N., Liss, M., Pittman, E., Muldong, M., et al. (2020). Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer. Journal of Translational Medicine, 18, 214.","journal-title":"Journal of Translational Medicine"},{"key":"10342_CR109","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/mt.2012.27","volume":"20","author":"A Pinc","year":"2012","unstructured":"Pinc, A., Somasundaram, R., Wagner, C., Hormann, M., Karanikas, G., Jalili, A., et al. (2012). Targeting CD20 in melanoma patients at high risk of disease recurrence. Molecular Therapy, 20, 1056\u20131062.","journal-title":"Molecular Therapy"},{"key":"10342_CR110","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s40425-019-0613-1","volume":"7","author":"W Damsky","year":"2019","unstructured":"Damsky, W., Jilaveanu, L., Turner, N., Perry, C., Zito, C., Tomayko, M., et al. (2019). B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. Journal for Immunotherapy of Cancer, 7, 153.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10342_CR111","doi-asserted-by":"crossref","unstructured":"Barbera-Guillem, E., Nelson, MB., Barr, B., Nyhus, JK., May, KF., Jr., Feng, L., et al. (2000). B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol Immunother, 48, 541\u20139.","DOI":"10.1007\/PL00006672"},{"key":"10342_CR112","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/annonc\/mdh280","volume":"15","author":"M Aklilu","year":"2004","unstructured":"Aklilu, M., Stadler, W. M., Markiewicz, M., Vogelzang, N. J., Mahowald, M., Johnson, M., et al. (2004). Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Annals of Oncology, 15, 1109\u20131114.","journal-title":"Annals of Oncology"},{"key":"10342_CR113","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1158\/0008-5472.CAN-12-4184","volume":"73","author":"M Bodogai","year":"2013","unstructured":"Bodogai, M., Lee Chang, C., Wejksza, K., Lai, J., Merino, M., Wersto, R. P., et al. (2013). Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. Cancer Research, 73, 2127\u20132138.","journal-title":"Cancer Research"},{"key":"10342_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100562","volume":"7","author":"M Simonelli","year":"2022","unstructured":"Simonelli, M., Garralda, E., Eskens, F., Gil-Martin, M., Yen, C. J., Obermannova, R., et al. (2022). Isatuximab plus atezolizumab in patients with advanced solid tumors: Results from a phase I\/II, open-label, multicenter study. ESMO Open, 7, Article 100562.","journal-title":"ESMO Open"},{"key":"10342_CR115","doi-asserted-by":"publisher","first-page":"9128","DOI":"10.1200\/JCO.2023.41.16_suppl.9128","volume":"41","author":"JM Clarke","year":"2023","unstructured":"Clarke, J. M., Stinchcombe, T., Gu, L., Mamdani, H., Antonia, S. J., Simon, G. R., et al. (2023). Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 41, 9128.","journal-title":"Journal of Clinical Oncology"},{"key":"10342_CR116","doi-asserted-by":"crossref","unstructured":"Mamdani, H., Clarke, JM., Gu, L., Stinchcombe, T., Crawford, J., Antonia, SJ., et al. (2024). Safety and efficacy of complement factor H (CFH) inhibitor GT103 in advanced non-small cell lung cancer (NSCLC): Results of a phase Ib first in human dose escalation study. Journal of Clinical Oncology, 42, e14588-e.","DOI":"10.1200\/JCO.2024.42.16_suppl.e14588"},{"key":"10342_CR117","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1002\/jcb.29441","volume":"121","author":"Z Yazdani","year":"2020","unstructured":"Yazdani, Z., Rafiei, A., Golpour, M., Zafari, P., Moonesi, M., & Ghaffari, S. (2020). IL-35, a double-edged sword in cancer. Journal of Cellular Biochemistry, 121, 2064\u20132076.","journal-title":"Journal of Cellular Biochemistry"},{"key":"10342_CR118","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.immuni.2016.01.013","volume":"44","author":"ME Turnis","year":"2016","unstructured":"Turnis, M. E., Sawant, D. V., Szymczak-Workman, A. L., Andrews, L. P., Delgoffe, G. M., Yano, H., et al. (2016). Interleukin-35 limits anti-tumor immunity. Immunity, 44, 316\u2013329.","journal-title":"Immunity"},{"key":"10342_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2024.156834","volume":"186","author":"RG Khalil","year":"2025","unstructured":"Khalil, R. G., Mohammed, D. A., Hamdalla, H. M., & Ahmed, O. M. (2025). The possible anti-tumor effects of regulatory T cells plasticity \/ IL-35 in the tumor microenvironment of the major three cancer types. Cytokine, 186, Article 156834.","journal-title":"Cytokine"},{"key":"10342_CR120","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.molimm.2012.03.025","volume":"51","author":"LL Jones","year":"2012","unstructured":"Jones, L. L., Chaturvedi, V., Uyttenhove, C., Van Snick, J., & Vignali, D. A. (2012). Distinct subunit pairing criteria within the heterodimeric IL-12 cytokine family. Molecular Immunology, 51, 234\u2013244.","journal-title":"Molecular Immunology"},{"key":"10342_CR121","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00535-022-01939-8","volume":"58","author":"T Tanaka","year":"2023","unstructured":"Tanaka, T., Masuda, A., Inoue, J., Hamada, T., Ikegawa, T., Toyama, H., et al. (2023). Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma. Journal of Gastroenterology, 58, 277\u201391.","journal-title":"Journal of Gastroenterology"},{"key":"10342_CR122","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1136\/gutjnl-2022-328697","volume":"72","author":"GS Kinker","year":"2023","unstructured":"Kinker, G. S., Vitiello, G. A. F., Diniz, A. B., Cabral-Piccin, M. P., Pereira, P. H. B., Carvalho, M. L. R., et al. (2023). Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas. Gut, 72, 1927\u20131941.","journal-title":"Gut"},{"key":"10342_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1569947","volume":"15","author":"L Hu","year":"2025","unstructured":"Hu, L., Xiao, Y., Jiang, N., Hu, Y., Qiu, L., & Geng, B. (2025). Investigating the correlation between tertiary lymphoid structures and clinical outcomes in pancreatic ductal adenocarcinoma: Insights into tumor immunology. Frontiers in Oncology, 15, Article 1569947.","journal-title":"Frontiers in Oncology"},{"key":"10342_CR124","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006698","author":"X Zou","year":"2023","unstructured":"Zou, X., Lin, X., Cheng, H., Chen, Y., Wang, R., Ma, M., et al. (2023). Characterization of intratumoral tertiary lymphoid structures in pancreatic ductal adenocarcinoma: Cellular properties and prognostic significance. Journal for ImmunoTherapy of Cancer. https:\/\/doi.org\/10.1136\/jitc-2023-006698","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10342_CR125","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1158\/2326-6066.CIR-25-0387","volume":"13","author":"DN Sidiropoulos","year":"2025","unstructured":"Sidiropoulos, D. N., Shin, S. M., Wetzel, M., Girgis, A. A., Bergman, D., Danilova, L., et al. (2025). Neoadjuvant immunotherapy promotes the formation of mature tertiary lymphoid structures in a remodeled pancreatic tumor microenvironment. Cancer Immunology Research, 13, 1716\u20131731.","journal-title":"Cancer Immunology Research"},{"key":"10342_CR126","doi-asserted-by":"crossref","unstructured":"Principe, D. R., (2026). The immunobiology of pancreatic cancer metastasis: premetastatic niche formation, organ-specific immune landscapes, and therapeutic opportunities. Cancer and Metastasis Reviews,\u00a045(2), 27.","DOI":"10.1007\/s10555-026-10334-1"},{"key":"10342_CR127","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ni.2366","volume":"13","author":"DA Vignali","year":"2012","unstructured":"Vignali, D. A., & Kuchroo, V. K. (2012). IL-12 family cytokines: Immunological playmakers. Nature Immunology, 13, 722\u2013728.","journal-title":"Nature Immunology"},{"key":"10342_CR128","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3389\/fimmu.2016.00479","volume":"7","author":"H Hasegawa","year":"2016","unstructured":"Hasegawa, H., Mizoguchi, I., Chiba, Y., Ohashi, M., Xu, M., & Yoshimoto, T. (2016). Expanding diversity in molecular structures and functions of the IL-6\/IL-12 heterodimeric cytokine family. Frontiers in Immunology, 7, 479.","journal-title":"Frontiers in Immunology"},{"key":"10342_CR129","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1600-065X.2008.00704.x","volume":"226","author":"LW Collison","year":"2008","unstructured":"Collison, L. W., & Vignali, D. A. (2008). Interleukin-35: Odd one out or part of the family? Immunological Reviews, 226, 248\u201362.","journal-title":"Immunological Reviews"},{"key":"10342_CR130","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.bbrc.2012.11.004","volume":"430","author":"J Long","year":"2013","unstructured":"Long, J., Zhang, X., Wen, M., Kong, Q., Lv, Z., An, Y., et al. (2013). IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells. Biochemical and Biophysical Research Communications, 430, 364\u2013369.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10342_CR131","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","volume":"23","author":"PG Richardson","year":"2022","unstructured":"Richardson, P. G., Perrot, A., San-Miguel, J., Beksac, M., Spicka, I., Leleu, X., et al. (2022). Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): Follow-up analysis of a randomised, phase 3 study. The lancet Oncology, 23, 416\u2013427.","journal-title":"The lancet Oncology"},{"key":"10342_CR132","first-page":"2239","volume":"109","author":"PG Richardson","year":"2024","unstructured":"Richardson, P. G., Perrot, A., Miguel, J. S., Beksac, M., Spicka, I., Leleu, X., et al. (2024). Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: Final overall survival analysis. Haematologica, 109, 2239\u20132249.","journal-title":"Haematologica"},{"key":"10342_CR133","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal, M., Richardson, P. G., Rajkumar, S. V., San-Miguel, J., Beksac, M., Spicka, I., et al. (2019). Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study. Lancet, 394, 2096\u20132107.","journal-title":"Lancet"},{"key":"10342_CR134","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra, S. V., Guzman, R. M., Gallacher, A. E., Hall, S., Levy, R. A., Jimenez, R. E., et al. (2011). Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet, 377, 721\u201331.","journal-title":"Lancet"},{"key":"10342_CR135","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2414719","volume":"393","author":"RF van Vollenhoven","year":"2025","unstructured":"van Vollenhoven, R. F., Wang, L., Merrill, J. T., Liu, Y., Bao, C., Li, F., et al. (2025). A phase 3 trial of telitacicept for systemic lupus erythematosus. New England Journal of Medicine, 393, 1475\u201385.","journal-title":"New England Journal of Medicine"},{"key":"10342_CR136","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/art.40360","volume":"70","author":"JT Merrill","year":"2018","unstructured":"Merrill, J. T., Wallace, D. J., Wax, S., Kao, A., Fraser, P. A., Chang, P., et al. (2018). Efficacy and safety of atacicept in patients with systemic lupus erythematosus: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis & Rheumatology, 70, 266\u201376.","journal-title":"Arthritis & Rheumatology"},{"key":"10342_CR137","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","volume":"105","author":"R Lafayette","year":"2024","unstructured":"Lafayette, R., Barbour, S., Israni, R., Wei, X., Eren, N., Floege, J., et al. (2024). A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney International, 105, 1306\u20131315.","journal-title":"Kidney International"},{"key":"10342_CR138","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","volume":"74","author":"D Isenberg","year":"2015","unstructured":"Isenberg, D., Gordon, C., Licu, D., Copt, S., Rossi, C. P., & Wofsy, D. (2015). Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Annals of the Rheumatic Diseases, 74, 2006\u201315.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10342_CR139","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.136417","author":"M Yarchoan","year":"2020","unstructured":"Yarchoan, M., Ho, W. J., Mohan, A., Shah, Y., Vithayathil, T., Leatherman, J., et al. (2020). Effects of B cell-activating factor on tumor immunity. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.136417","journal-title":"JCI Insight"},{"key":"10342_CR140","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41568-024-00728-0","volume":"24","author":"JL Teillaud","year":"2024","unstructured":"Teillaud, J. L., Houel, A., Panouillot, M., Riffard, C., & Dieu-Nosjean, M. C. (2024). Tertiary lymphoid structures in anticancer immunity. Nature Reviews. Cancer, 24, 629\u2013646.","journal-title":"Nature Reviews. Cancer"},{"key":"10342_CR141","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejca.2021.01.036","volume":"148","author":"CS Groeneveld","year":"2021","unstructured":"Groeneveld, C. S., Fontugne, J., Cabel, L., Bernard-Pierrot, I., Radvanyi, F., Allory, Y., et al. (2021). Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. European Journal of Cancer, 148, 181\u2013189.","journal-title":"European Journal of Cancer"},{"key":"10342_CR142","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122092","author":"AC Hopkins","year":"2018","unstructured":"Hopkins, A. C., Yarchoan, M., Durham, J. N., Yusko, E. C., Rytlewski, J. A., Robins, H. S., et al. (2018). T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.122092","journal-title":"JCI Insight"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10342-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10342-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10342-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:03:24Z","timestamp":1779426204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-026-10342-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":142,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["10342"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10342-1","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"5 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Generative AI and AI-assisted technologies were not used in the preparation of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"AI statement"}}],"article-number":"35"}}